Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic

Post time 2024-6-17 18:46:01

Edited by khacthuanprovip at 2024-6-17 18:46

journal：Diabetes, Obesity and Metabolism

Authors：Bao‐Ngoc Nguyen; Le Nguyen; Shweta Mital; Shawn Bugden; Hai V. Nguyen

Published date：2023-6-

DOI：10.1111/dom.15009

PDF link：https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.15009

Article link：http://dx.doi.org/10.1111/dom.15009

Article Source：Wiley。

Remark：

Post time 2024-6-17 18:46:02

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Wiley] Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Wiley] Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Wiley] Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic